<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OL</journal-id>
<journal-title-group>
<journal-title>Oncology Letters</journal-title>
</journal-title-group>
<issn pub-type="ppub">1792-1074</issn>
<issn pub-type="epub">1792-1082</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/ol.2020.12079</article-id>
<article-id pub-id-type="publisher-id">OL-0-0-12079</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Reduced I&#x03BA;B&#x03B1; promotes hepatocellular carcinoma cell proliferation and migration via regulation of NF-&#x03BA;B/Erbin axis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Tan</surname><given-names>Ye</given-names></name>
<xref rid="af1-ol-0-0-12079" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Lin</surname><given-names>Xiao-Tong</given-names></name>
<xref rid="af1-ol-0-0-12079" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Luo</surname><given-names>Yuan-Deng</given-names></name>
<xref rid="af1-ol-0-0-12079" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Jie</given-names></name>
<xref rid="af1-ol-0-0-12079" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Fang</surname><given-names>Lei</given-names></name>
<xref rid="af1-ol-0-0-12079" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Yan-Yin</given-names></name>
<xref rid="af1-ol-0-0-12079" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Yu</surname><given-names>Hong-Qiang</given-names></name>
<xref rid="af1-ol-0-0-12079" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Shuai</surname><given-names>Ling</given-names></name>
<xref rid="af1-ol-0-0-12079" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Yan</given-names></name>
<xref rid="af1-ol-0-0-12079" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Lei-Da</given-names></name>
<xref rid="af1-ol-0-0-12079" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Bie</surname><given-names>Ping</given-names></name>
<xref rid="af1-ol-0-0-12079" ref-type="aff">1</xref>
<xref rid="af2-ol-0-0-12079" ref-type="aff">2</xref>
<xref rid="c1-ol-0-0-12079" ref-type="corresp"/></contrib>
<contrib contrib-type="author"><name><surname>Xie</surname><given-names>Chuan-Ming</given-names></name>
<xref rid="af1-ol-0-0-12079" ref-type="aff">1</xref>
<xref rid="c1-ol-0-0-12079" ref-type="corresp"/></contrib>
</contrib-group>
<aff id="af1-ol-0-0-12079"><label>1</label>Key Laboratory of Hepatobiliary and Pancreatic Surgery, Institute of Hepatobiliary Surgery, Southwest Hospital, Army Medical University, Chongqing 400038, P.R. China</aff>
<aff id="af2-ol-0-0-12079"><label>2</label>Department of Hepatobiliary and Pancreatic Surgery, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, P.R. China</aff>
<author-notes>
<corresp id="c1-ol-0-0-12079"><italic>Correspondence to</italic>: Professor Chuan-Ming Xie or Professor Ping Bie, Key Laboratory of Hepatobiliary and Pancreatic Surgery, Institute of Hepatobiliary Surgery, Southwest Hospital, Army Medical University, 30 Gaotanyan Street, Chongqing 400038, P.R. China, E-mail: <email>chuanming506@126.com</email>, E-mail: <email>bieping1209@sina.com</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>11</month>
<year>2020</year></pub-date>
<pub-date pub-type="epub">
<day>09</day>
<month>09</month>
<year>2020</year></pub-date>
<volume>20</volume>
<issue>5</issue>
<elocation-id>216</elocation-id>
<history>
<date date-type="received"><day>23</day><month>03</month><year>2020</year></date>
<date date-type="accepted"><day>19</day><month>06</month><year>2020</year></date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; Tan et al.</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license>
</permissions>
<abstract>
<p>Aberrantly low expression of NF-&#x03BA;B inhibitor &#x03B1; (I&#x03BA;B&#x03B1;) is observed in hepatocellular carcinoma (HCC), yet the underlying mechanism via which I&#x03BA;B&#x03B1; regulates HCC remains largely unknown. Therefore, to determine the potential function of I&#x03BA;B&#x03B1; in hepatocarcinogenesis, the present study used immunohistochemistry (IHC) staining to analyze the associations between I&#x03BA;B&#x03B1; protein expression and clinicopathologic characteristics of 107 patients with HCC. It was found that expression of I&#x03BA;B&#x03B1; was significantly associated with tumor recurrence. Moreover, I&#x03BA;B&#x03B1; protein expression was decreased in 107 HCC tissue samples and was positively associated with overall survival. Mechanistically, it was demonstrated that silencing of I&#x03BA;B&#x03B1; activated NF-&#x03BA;B in both Huh7 and HCCLM3 cells, followed by upregulation of Erbb2 interacting protein (Erbin) at both the mRNA and protein levels, confirmed by reverse transcription-quantitative PCR and western blotting, to promote cell proliferation and migration. Furthermore, knockdown of Erbin significantly attenuated NF-&#x03BA;B-mediated cell proliferation and migration. It was also identified that overexpression of Erbin in HCC tissues promoted both cell proliferation and migration, and was negatively associated with I&#x03BA;B&#x03B1; expression in 107 HCC tissue samples. Thus, these results indicated that downregulation of I&#x03BA;B&#x03B1; promoted HCC tumorigenesis via upregulation of NF-&#x03BA;B-mediated Erbin expression.</p>
</abstract>
<kwd-group>
<kwd>I&#x03BA;B&#x03B1;</kwd>
<kwd>Erbb2 interacting protein</kwd>
<kwd>HCC</kwd>
<kwd>tumorigenesis</kwd>
</kwd-group></article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Hepatocellular carcinoma (HCC) is one of the most malignant cancer types worldwide, especially in east Asia (<xref rid="b1-ol-0-0-12079" ref-type="bibr">1</xref>). Although significant improvements in diagnosis and treatment have been accomplished, the mortality rate for patients with HCC remains high, with ~782,000 deaths worldwide annually (<xref rid="b1-ol-0-0-12079" ref-type="bibr">1</xref>&#x2013;<xref rid="b3-ol-0-0-12079" ref-type="bibr">3</xref>). The rapid and unnoticeable development and metastases of HCC are crucial to its progression, resulting in unresectable vascular thrombi, intrahepatic satellite nodules or cancer recurrence (<xref rid="b4-ol-0-0-12079" ref-type="bibr">4</xref>,<xref rid="b5-ol-0-0-12079" ref-type="bibr">5</xref>). Hence, it is important to discover effective diagnostic biomarkers to identify HCC in the early stage to improve the prognosis of patients with HCC.</p>
<p>NF-&#x03BA;B inhibitor &#x03B1; (I&#x03BA;B&#x03B1;) is an isoform in the I&#x03BA;B family, members of which have multiple ankyrin repeat domains at the C-terminus (<xref rid="b6-ol-0-0-12079" ref-type="bibr">6</xref>). I&#x03BA;B&#x03B1; combines with the NF-&#x03BA;B dimer to retain its existence in the cytoplasm and prevent its translocation into the nucleus (<xref rid="b6-ol-0-0-12079" ref-type="bibr">6</xref>). The I&#x03BA;B kinase (IKK) complex is induced by diverse extracellular signals, such as lipopolysaccharide, tumor necrosis factor (TNF) and growth factors, and the activated IKK complex phosphorylates I&#x03BA;B&#x03B1;. Then, phosphorylated I&#x03BA;B&#x03B1; is specifically recognized by an E3 ubiquitin ligase, leading to its ubiquitination and degradation (<xref rid="b7-ol-0-0-12079" ref-type="bibr">7</xref>). While previous studies have reported its inhibition of NF-&#x03BA;B, the remaining functions of I&#x03BA;B&#x03B1; in HCC are yet to be fully elucidated.</p>
<p>p65 is a well-known member of the NF-&#x03BA;B family of transcriptional factors participating in numerous pathways in biological responses, such as inflammation, adaptive immunity and stress reactions (<xref rid="b8-ol-0-0-12079" ref-type="bibr">8</xref>). Previous studies have revealed that NF-&#x03BA;B is involved in cancer oncogenesis and that it specifically promotes proliferation, metastasis and cell survival, particularly in inflammation-related cancer types (<xref rid="b9-ol-0-0-12079" ref-type="bibr">9</xref>,<xref rid="b10-ol-0-0-12079" ref-type="bibr">10</xref>). In healthy cells, activation of NF-&#x03BA;B after interaction with cellular stimuli occurs for a short duration and then returns to the inactive form. However, NF-&#x03BA;B is activated aberrantly in cancer cells, and thus continues to upregulate the transcription of its target gene (<xref rid="b11-ol-0-0-12079" ref-type="bibr">11</xref>). To achieve its transcriptional function, NF-&#x03BA;B/Rel proto-oncogene, NF-&#x03BA;B subunit (Rel) complex should shuttle to nucleus; but, I&#x03BA;B&#x03B1; combines with the dimer to anchor it in cytoplasm and thus inhibit its activity (<xref rid="b8-ol-0-0-12079" ref-type="bibr">8</xref>). After its phosphorylation is initiated by proinflammation signals or immune stimulation, I&#x03BA;B&#x03B1; is degraded by the ubiquitin-protease system, which enables the NF-&#x03BA;B/Rel dimer to translocate in nucleus (<xref rid="b12-ol-0-0-12079" ref-type="bibr">12</xref>). Therefore, reduced expression of I&#x03BA;B&#x03B1; is an important cause of the abnormal elevated expression of NF-&#x03BA;B in cancer cells.</p>
<p>Erbb2 interacting protein (Erbin) is a target gene of NF-&#x03BA;B, encoding Erbin. Containing 16 leucine-rich repeats and one PSD-95/Dlg/ZO-1 (PDZ) domain, Erbin is a member of the leucine-rich repeat and PDZ domain family (<xref rid="b13-ol-0-0-12079" ref-type="bibr">13</xref>). Furthermore, Erbin is an adaptor of the Erb-b2 receptor tyrosine kinase 2 (ERBB2) protein and, by binding with ERBB2, regulates its function and localization (<xref rid="b13-ol-0-0-12079" ref-type="bibr">13</xref>). Erbin has also been reported to be involved in several pathways (<xref rid="b14-ol-0-0-12079" ref-type="bibr">14</xref>). For instance, Erbin suppresses tumorigenesis via inhibiting Akt activity or Ras/Raf signaling (<xref rid="b15-ol-0-0-12079" ref-type="bibr">15</xref>,<xref rid="b16-ol-0-0-12079" ref-type="bibr">16</xref>). In addition, Erbin exerts an ontogenetic function by activating estrogen receptor (ER) &#x03B1; or inhibiting STAT3 signaling (<xref rid="b17-ol-0-0-12079" ref-type="bibr">17</xref>,<xref rid="b18-ol-0-0-12079" ref-type="bibr">18</xref>). Thus, there is conflicting data regarding the role of Erbin in cancer. A previous study showed that Erbin is upregulated following exposure of macrophages to muramyl dipeptide, TNF &#x03B1; and lipopolysaccharide (<xref rid="b19-ol-0-0-12079" ref-type="bibr">19</xref>). Although it has been observed that Erbin is upregulated in HCC tissues, the underlying mechanism via which Erbin becomes dysregulated remains unknown.</p>
<p>The present study investigated the clinical importance of I&#x03BA;B&#x03B1;, Erbin and their molecular interactions, which suggested that reduced I&#x03BA;B&#x03B1; expression promoted HCC cell proliferation and migration via the NF-&#x03BA;B/Erbin pathway. Mechanistically, I&#x03BA;B&#x03B1; was downregulated in HCC tissues compared with healthy liver tissues, and decreased expression of I&#x03BA;B&#x03B1; weakened the inhibition of NF-&#x03BA;B. Abnormally activated NF-&#x03BA;B promoted Erbin expression at both the mRNA and protein levels, which served an oncogenic function in HCC. Moreover, I&#x03BA;B&#x03B1; was negatively associated with Erbin, and decreased I&#x03BA;B&#x03B1; and increased Erbin expression levels were associated with poor outcomes in patients with HCC. Therefore, the present results may facilitate the development of a potential strategy to target Erbin for HCC treatment.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Patients with HCC and sample collection</title>
<p>In all, 107 human HCC tissue specimens were acquired from patients (aged between 19 and 73 years old, and 93 male, 14 female) between January 2011 and December 2013 at the Department of Hepatobiliary Surgery of Southwest Hospital, Army Medical University (Chongqing, China). All patients provided written informed consent and this study obtained approval from the Ethics Committee of Southwest Hospital. All patients used in this study were followed up for 5 years since their cancer diagnosis. Upon acquisition, HCC and paracancerous liver tissues (free of tumor to the eye) were conventionally 10&#x0025; formalin-fixed for 48 h on a rotator at room temperature, paraffin-embedded and cut into 10-&#x00B5;m sections.</p>
</sec>
<sec>
<title>Immunohistochemistry (IHC) staining</title>
<p>To perform IHC staining, sections were first deparaffinized, rehydrated and then boiled for 2.5 min in 100&#x00B0;C 0.01 mol/l sodium citrate solution for antigen retrieval. Then the IHC detection kit (SP-9001; ZSGB-Bio, Beijing, China) was employed from blockage of peroxidase to incubation of secondary antibodies according to the manufacturer&#x0027;s instructions. Briefly, 3&#x0025; H<sub>2</sub>O<sub>2</sub> was used to block the endogenous peroxidase at room temperature for 15 min. After blocking with 5&#x0025; goat serum at room temperature for 30 min, tissues were incubated with specific antibodies: Anti-I&#x03BA;B&#x03B1; (sc-945; 1:50 dilution; Santa Cruz Biotechnology, Inc.) and anti-Erbin (22438&#x2013;1-AP; 1:50 dilution; ProteinTech Group, Inc.) overnight at 4&#x00B0;C. The following day the sections were incubated with horseradish peroxidase-conjugated secondary antibody, before positive signals were detected using 3,3&#x2032;-diaminobenzidine and nuclei were stained with hematoxylin at room temperature for 20 sec. After dehydration, representative images were captured with an Olympus BX41 microscope under bright field (magnification, &#x00D7;100). Histological grading was referred to clinical standards (<xref rid="b20-ol-0-0-12079" ref-type="bibr">20</xref>).</p>
</sec>
<sec>
<title>Cell culture and transfection</title>
<p>Huh7 and HCCLM3 cells were purchased from Fudan Cell Bank (Shanghai, China). Cells were maintained in DMEM (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10&#x0025; FBS (Gibco; Thermo Fisher Scientific, Inc.) and 1&#x0025; penicillin-streptomycin solution (Gibco; Thermo Fisher Scientific, Inc.), and cultured at 37&#x00B0;C with 5&#x0025; CO<sub>2</sub>.</p>
<p>Cell transfection with plasmids (HA-tagged I&#x03BA;B&#x03B1;, Flag-tagged NF-&#x03BA;B p65 and corresponding empty vector as control; all Shanghai GeneChem Co., Ltd.) or small interfering RNAs (siRNAs; Shanghai Genepharma Co., Ltd.) was performed using Lipofectamine<sup>&#x00AE;</sup> 2000 (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer&#x0027;s instructions. In total, 400,000 cells/well were seeded into 6-well plates 1 day before transfection. Plasmids or siRNAs were diluted in Opti-MEM (Gibco; Thermo Fisher Scientific, Inc.) before mixing with Lipofectamine<sup>&#x00AE;</sup> 2000. Overexpression vector plasmids were pcDNA3.1 (Shanghai GeneChem Co., Ltd.). Each well of the 6-well plate was added with 2 &#x00B5;g plasmid for transfection. The sequences of siRNA oligos were: siI&#x03BA;B&#x03B1;, 5&#x2032;-CUCCGAGACUUUCGAGGAATT-3&#x2032;; siNF-&#x03BA;B p65, 5&#x2032;-GAUUGAGGAGAAACGUAAAdTdT-3&#x2032;; and siErbin, 5&#x2032;-CACACUGUUGUAUGAUCAACCAU-3&#x2032;. Each well of a 6-well plate was added with 8 &#x00B5;l siRNA (20 &#x00B5;mol/l) for transfection. After 48 h, cells were harvested for successive experiments.</p>
</sec>
<sec>
<title>Cell Counting Kit (CCK)-8</title>
<p>Cell proliferation was assessed using CCK-8 according to the instructions of the manufacturer (Bimake). Then, 24 h after transfection, cells were trypsinized and counted manually. Cells (2,000-3,000 cells/well) were seeded into a 96-well plate and after another 24 h, 10 &#x00B5;l CCK-8 solution was added into each well. The cells were incubated at 37&#x00B0;C for another 2&#x2013;4 h. A spectrophotometer was then used to measure absorbance at 450 nm.</p>
</sec>
<sec>
<title>Clonogenic survival assay</title>
<p>Transfected cells in DMEM with 10&#x0025; FBS were seeded into 6-well plate, ~500 cells per well. After 10&#x2013;14 days, cells that formed visualized colonies were stained with 0.1&#x0025; crystal violet staining solution (Beijing Solarbio Science &#x0026; Technology Co., Ltd.) at room temperature for 30 min and images were captured. Colonies with &#x003E;50 cells were counted manually.</p>
</sec>
<sec>
<title>Transwell migration assay</title>
<p>To compare the difference of cell migration after different transfection, 5&#x00D7;10<sup>4</sup>&#x2212;1.5&#x00D7;10<sup>5</sup> transfected cells were plated into an 8 &#x00B5;m-pore Transwell chamber, fit for a 24-well plate, with serum free-DMEM. The lower section of the chamber, a 24-well plate, contained normal medium with 10&#x0025; FBS. FBS acted as attractant to stimulate cell migrate through the membrane of chambers. After incubating for 24 h, cells were fixed by 4&#x0025; paraformaldehyde for 15 min at room temperature and stained with 0.1&#x0025; crystal violet staining solution (Beijing Solarbio Science &#x0026; Technology Co., Ltd.) at room temperature for 30 min. Three different fields were captured under bright field and cells were counted manually (magnification, &#x00D7;40).</p>
</sec>
<sec>
<title>RNA extraction and reverse transcription-quantitative (RT-q)PCR</title>
<p>RNA extraction, reverse transcription (RT) and real-time PCR were performed using RNAiso Plus, PrimeScript&#x2122; RT reagent kit with gDNA Eraser (Perfect Real Time) and TB Green Premix Ex Taq (Tli RNaseH Plus) (all Takara Bio, Inc.), following the manufacturer&#x0027;s instructions. Temperature and duration for reverse transcription were 37&#x00B0;C for 15 min and 85&#x00B0;C for 5 min. The thermocycling conditions were as follows: Activation of enzyme at 95&#x00B0;C for 30 sec; 30 cycles of denaturation and annealing at 95&#x00B0;C for 5 sec and 60&#x00B0;C for 30 sec. GAPDH was used as the reference gene. The quantitative method to analyze relative gene expression was 2<sup>&#x2212;&#x0394;&#x0394;Cq</sup> (<xref rid="b21-ol-0-0-12079" ref-type="bibr">21</xref>). The 5&#x2032;-3&#x2032;sequences of primers used in RT-qPCR were as follows: GAPDH forward, TGGCACCGTCAAGGCTGAGAA and reverse, TGGTGAAGACGCCAGTGGACTC; NF-&#x03BA;B p65 forward, CGCTGCATCCACAGTTTCCA and reverse, AGGGGTTGTTGTTGGTCTGG; Erbin forward, TGTGGGTGTGAAGACCTCAG and reverse, GTCGCATCTCCGCCATTTTC; c-Rel forward GGTTGGTCCTGCCTCCTTAC, and reverse, GCTGGAGTCCCAATGACGAA; and enhancer of zeste 2 polycomb repressive complex 2 subunit (Ezh2) forward, GGACCACAGTGTTACCAGCAT and reverse, GTGGGGTCTTTATCCGCTCAG.</p>
</sec>
<sec>
<title>Western blot analysis</title>
<p>Proteins were extracted using RIPA lysis buffer (Beyotime Institute of Biotechnology) with complete protease inhibitor cocktail tablet (Bimake). Protein concentration was calculated by a BCA protein concentration kit (Beyotime Institute of Biotechnology) and 5X SDS loading buffer (Shanghai Shenggong Biology Engineering Technology Service, Ltd.) was added for extraction. The samples were gently vortexed and boiled at 100&#x00B0;C for 10 min before 30 &#x00B5;g was loaded onto 10&#x0025; polyacrylamide gel (EpiZyme, Inc.). Following electrophoresis, proteins were transferred to nitrocellulose membranes. The membranes were blocked in 5&#x0025; non-fat milk solution at room temperature for at least 1 h, incubated with primary antibodies at 4&#x00B0;C overnight and then HRP-conjunct secondary antibodies at room temperature for 1 h. Protein blots were detected using the super ECL kit (Nanjing KeyGen Biotech Co., Ltd.). Antibodies used in this study were: Anti-I&#x03BA;B&#x03B1; (sc-945, 1:600 dilution, Santa Cruz Biotechnology, Inc.); anti-NF-&#x03BA;B p65 (#8242, 1:1,000 dilution, Cell Signaling Technology, Inc.); anti-GAPDH (10494-1-AP, 1:5,000 dilution, ProteinTech group, Inc.) and anti-Erbin (22438-1-AP, 1:500 dilution, ProteinTech group, Inc.).</p>
</sec>
<sec>
<title>Statistics analysis</title>
<p>Data are presented as the mean &#x00B1; SEM, which represented &#x2265;3 independent trials. Comparison between two different groups was performed using unpaired Student&#x0027;s t-test. Comparison among multiple groups was performed using one-way ANOVA and least significance difference was used as the post hoc test. &#x03C7;<sup>2</sup> test was used to detect associations between protein expression and clinical characteristics. Survival analysis was performed using Kaplan-Meier method and comparisons with the log-rank test. Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software, Inc.) and SPSS software (22.0 version; IBM Corp.). P&#x003C;0.05 was considered to indicate a statistically significant difference.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>I&#x03BA;B&#x03B1; expression is downregulated in HCC and positively associated with poor prognosis of patients with HCC</title>
<p>The results indicated that I&#x03BA;B&#x03B1; protein expression was markedly decreased in HCC tissues compared with adjacent tissues (<xref rid="f1-ol-0-0-12079" ref-type="fig">Fig. 1A</xref>). In total, 77.6&#x0025; (83/107) of HCC cases exhibited low expression compared with the matched peri-tumor tissues. Kaplan-Meier survival analysis demonstrated that patients with HCC with low expression of I&#x03BA;B&#x03B1; had a significantly shorter survival time compared with patients with high expression (<xref rid="f1-ol-0-0-12079" ref-type="fig">Fig. 1B</xref>). In addition, the association between the expression of I&#x03BA;B&#x03B1; and cancer recurrence was statistically significant (<xref rid="tI-ol-0-0-12079" ref-type="table">Table I</xref>).</p>
<p>To determine the tumor suppressive function of I&#x03BA;B&#x03B1;, CCK-8, clonogenic survival and Transwell migration assays were used to detect proliferation and migration of HCC cells. Knockdown of I&#x03BA;B&#x03B1; significantly promoted cell proliferation and migration, whereas overexpression of I&#x03BA;B&#x03B1; significantly inhibited cell proliferation and migration (<xref rid="f1-ol-0-0-12079" ref-type="fig">Fig. 1C-H</xref>). These findings suggested that I&#x03BA;B&#x03B1; was downregulated in HCC tissues and that knockdown of I&#x03BA;B&#x03B1; was positively associated with poor prognosis of patients with HCC.</p>
</sec>
<sec>
<title>I&#x03BA;B&#x03B1; negatively regulates Erbin expression via NF-&#x03BA;B</title>
<p>Although it has been reported that elevated Erbin promotes HCC tumorigenesis (<xref rid="b18-ol-0-0-12079" ref-type="bibr">18</xref>), the underlying mechanism via which Erbin is upregulated in HCC remains unknown. The results indicated that Erbin expression was upregulated in the HCC tissues from 107 patients in southwest of China (<xref rid="f2-ol-0-0-12079" ref-type="fig">Fig. 2A</xref>). Kaplan-Meier survival analysis demonstrated that high expression of Erbin was positively associated with short survival time of patients with HCC (<xref rid="f2-ol-0-0-12079" ref-type="fig">Fig. 2B</xref>). Moreover, expression of Erbin was associated with malignant characteristics of HCC, such as TNM stage, existence of vascular tumor thrombi and cancer recurrence (<xref rid="tII-ol-0-0-12079" ref-type="table">Table II</xref>). As both I&#x03BA;B&#x03B1; and Erbin are associated with poor survival of patients with HCC, it was determined whether there was an association between I&#x03BA;B&#x03B1; and Erbin. It was found that knockdown of I&#x03BA;B&#x03B1; promoted Erbin protein expression, while overexpression of I&#x03BA;B&#x03B1; reduced this expression (<xref rid="f2-ol-0-0-12079" ref-type="fig">Fig. 2C and D</xref>).</p>
<p>NF-&#x03BA;B/Rel transcription factors present in the cytosol in an inactive state form a complex with inhibitory I&#x03BA;B proteins (<xref rid="b7-ol-0-0-12079" ref-type="bibr">7</xref>). It has been suggested that NF-&#x03BA;B p65 is released from combination with I&#x03BA;B&#x03B1; and nuclear translocation occurs when I&#x03BA;B&#x03B1; is downregulated in HCC (<xref rid="b6-ol-0-0-12079" ref-type="bibr">6</xref>). The results indicated that knockdown of I&#x03BA;B&#x03B1; increased NF-&#x03BA;B p65 expression (<xref rid="f2-ol-0-0-12079" ref-type="fig">Fig. 2E</xref>), while overexpression of I&#x03BA;B&#x03B1; inhibited NF-&#x03BA;B p65 expression (<xref rid="f2-ol-0-0-12079" ref-type="fig">Fig. 2F</xref>). Subsequently, NF-&#x03BA;B activation upon I&#x03BA;B knockdown was examined, as indicated by activation of canonical and non-canonical transcriptional targets of NF-&#x03BA;B, c-Rel and Ezh2 after transfection of siI&#x03BA;B&#x03B1; (<xref rid="f2-ol-0-0-12079" ref-type="fig">Fig. 2G</xref>).</p>
<p>To assess whether the transcription factor NF-&#x03BA;B regulates Erbin, the effect of knockdown or overexpression of NF-&#x03BA;B on Erbin at the mRNA and protein levels was measured. In contrast to I&#x03BA;B&#x03B1;, overexpression of NF-&#x03BA;B enhanced both mRNA and protein expression levels of Erbin, whereas knockdown of NF-&#x03BA;B inhibited these expression levels (<xref rid="f2-ol-0-0-12079" ref-type="fig">Fig. 2H-K</xref>). Collectively, the results indicated that reduced I&#x03BA;B&#x03B1; promoted NF-&#x03BA;B-mediated Erbin expression at both mRNA and protein levels.</p>
</sec>
<sec>
<title>I&#x03BA;B&#x03B1; is negatively associated with Erbin in patients with HCC</title>
<p>To further evaluate the association between I&#x03BA;B&#x03B1; and Erbin, the expression levels of I&#x03BA;B&#x03B1; and Erbin were analyzed in 107 HCC tissues using IHC staining. It was determined that 77.6&#x0025; of HCC samples were I&#x03BA;B&#x03B1;-negative or low expression, demonstrating active NF-&#x03BA;B signaling in the majority of cases (<xref rid="f3-ol-0-0-12079" ref-type="fig">Fig. 3A and B</xref>). In line with this finding, Erbin protein expression in 58.9&#x0025; (63/107) of cases was upregulated compared with the adjacent tissues. Thus, there was a negative association between I&#x03BA;B&#x03B1; and Erbin expression levels in HCC tissues (<xref rid="f3-ol-0-0-12079" ref-type="fig">Fig. 3</xref>).</p>
</sec>
<sec>
<title>Erbin is responsible for NF-&#x03BA;B-mediated HCC cell proliferation and migration</title>
<p>Based on the oncogenic function of NF-&#x03BA;B (<xref rid="b22-ol-0-0-12079" ref-type="bibr">22</xref>) and its positive regulation over Erbin, it was evaluated whether Erbin was responsible for NF-&#x03BA;B-mediated cell proliferation and migration. Overexpression of NF-&#x03BA;B upregulated Erbin expression, and overexpression of Erbin exerted oncogenic effects on the proliferation and migration of HCC cells. However, knockdown of Erbin attenuated the aforementioned cellular abilities (<xref rid="f4-ol-0-0-12079" ref-type="fig">Fig. 4A-F</xref>). In addition, increased proliferation and migration of HCC cells by NF-&#x03BA;B overexpression was reversed by Erbin knockdown (<xref rid="f4-ol-0-0-12079" ref-type="fig">Fig. 4G-I</xref>), indicating that NF-&#x03BA;B promoted its activities via Erbin signaling. In healthy liver tissues, expression of I&#x03BA;B&#x03B1; limited the activity of NF-&#x03BA;B (<xref rid="b6-ol-0-0-12079" ref-type="bibr">6</xref>) and, in turn, its downstream target Erbin according to the present results. However, in HCC, NF-&#x03BA;B was abnormally activated due to the absence of I&#x03BA;B&#x03B1;, and transcriptionally upregulated expression of Erbin stimulated the proliferation and migration of HCC cells.</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>As HCC is a serious and lethal disease worldwide (<xref rid="b1-ol-0-0-12079" ref-type="bibr">1</xref>), and thus it is important to determine a novel therapeutic target. The present study identified that in HCC tissues, there was low expression of I&#x03BA;B&#x03B1;, the inhibitor of NF-&#x03BA;B, and decreased expression of I&#x03BA;B&#x03B1; promoted cancer cell proliferation and migration. Once I&#x03BA;B&#x03B1; undergoes proteasomal degradation, NF-&#x03BA;B activity is initiated (<xref rid="b6-ol-0-0-12079" ref-type="bibr">6</xref>), and positively affects cell proliferation and migration by promoting the expression of Erbin. In the current study, consistent with previous reports of increased Erbin expression in HCC tissues obtained from Shanghai (<xref rid="b18-ol-0-0-12079" ref-type="bibr">18</xref>), the results indicated Erbin expression was upregulated in HCC tissues from 107 patients in southwest of China and exerted oncogenic functions. Moreover, downregulation of I&#x03BA;B&#x03B1; and upregulation of Erbin were closely associated with poor prognosis of patients with HCC. Therefore, the present results demonstrated the clinical importance of I&#x03BA;B&#x03B1; and Erbin, identified a novel association between I&#x03BA;B&#x03B1;/NF-&#x03BA;B and indicated the role of the downstream oncoprotein Erbin in the promotion of HCC tumorigenesis.</p>
<p>I&#x03BA;B&#x03B1; is considered to be a tumor-suppressing factor in different types of cancer, such as breast (<xref rid="b23-ol-0-0-12079" ref-type="bibr">23</xref>,<xref rid="b24-ol-0-0-12079" ref-type="bibr">24</xref>), ovarian (<xref rid="b25-ol-0-0-12079" ref-type="bibr">25</xref>), gastric (<xref rid="b26-ol-0-0-12079" ref-type="bibr">26</xref>) and colorectal (<xref rid="b27-ol-0-0-12079" ref-type="bibr">27</xref>), mainly due to its inhibition of NF-&#x03BA;B activity; however, the underlying mechanism is yet to be elucidated. Liver tumorigenesis is usually attributed to inflammation (<xref rid="b28-ol-0-0-12079" ref-type="bibr">28</xref>). Cell proliferation increases during inflammation, in which accelerated DNA replication results in the increased occurrence of oncogenic mutation (<xref rid="b29-ol-0-0-12079" ref-type="bibr">29</xref>). Moreover, NF-&#x03BA;B, as a hallmark of inflammation, not only participates in the initiation, but also maintains inflammation via blocking apoptosis, together with TNF&#x03B1; to activate anti-apoptosis genes (<xref rid="b30-ol-0-0-12079" ref-type="bibr">30</xref>). Thus, NF-&#x03BA;B serves a crucial role in promoting inflammation and contributing to malignancy (<xref rid="b31-ol-0-0-12079" ref-type="bibr">31</xref>).</p>
<p>Erbin has been reported to exert a range of diverse functions. For example, Erbin suppresses the activity of the Ras/Raf pathway to inhibit proliferation and stop epithelial-mesenchymal transition progress in colorectal cancer (<xref rid="b32-ol-0-0-12079" ref-type="bibr">32</xref>). Deficiency of Erbin significantly promotes ERK phosphorylation in ERBB2-overexpressed breast cancer (<xref rid="b33-ol-0-0-12079" ref-type="bibr">33</xref>). Furthermore, accumulation of Erbin attenuates Raf activation to halt autophagy and senescence in KRAS proto-oncogene, GTPase-induced skin tumorigenesis (<xref rid="b34-ol-0-0-12079" ref-type="bibr">34</xref>). Erbin also exerts a pro-tumorigenesis role by negatively regulating ER&#x03B1; (<xref rid="b18-ol-0-0-12079" ref-type="bibr">18</xref>). Therefore, these findings suggest that the function of Erbin depends closely on cell types or a certain cancer microenvironment. The current study demonstrated a novel signaling via which NF-&#x03BA;B promotes tumorigenesis. It was indicated that in HCC, Erbin is highly expressed and associated with poor prognosis of patients. In HCC cells, it was identified that NF-&#x03BA;B activated the expression of Erbin at both the mRNA and protein levels, and overexpression of Erbin enhanced cell proliferation and migration, while its knockdown reduced these abilities.</p>
<p>In conclusion, the present study identified that: i) I&#x03BA;B&#x03B1; was decreased in HCC and associated with poor survival of patients with HCC; ii) knockdown of I&#x03BA;B&#x03B1; upregulated NF-&#x03BA;B signaling to promote HCC cell proliferation and migration; and iii) NF-&#x03BA;B-mediated Erbin upregulation contributes to HCC cell proliferation and migration and a poor outcome of patients with HCC. Therefore, the present results indicated the important clinical implications of I&#x03BA;B&#x03B1; and Erbin, as well as the novel NF-&#x03BA;B/Erbin oncogenic pathway. Thus, disruption of this signaling pathway may be a novel strategy to slow the progression of HCC.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>Not applicable.</p>
</ack>
<sec>
<title>Funding</title>
<p>This work was supported by the Introduction of Special Funds for Talents from Army Medical University (grant no. 4174C6), Natural Science Foundation of Chongqing (grant no. cstc2019jcyjmsxmX0519) and the Natural Science Foundation (grant no. 4241212I62).</p>
</sec>
<sec>
<title>Availability of data and materials</title>
<p>The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.</p>
</sec>
<sec>
<title>Authors&#x0027; contributions</title>
<p>CMX designed and supervised the study. YT, XTL, YDL, JZ, LF, YYZ, HQY and LDZ performed the experiments. YT, YYZ, HQY and CMX contributed to immunohistochemistry analysis and pathological analysis. YJ and LS contributed to the clinical sample collection, fixing and embedding, and pathological information processing. YT, PB and CMX analyzed and interpreted the data. YT and CMX drafted the manuscript. All authors read and approved the final manuscript.</p>
</sec>
<sec>
<title>Ethics approval and consent to participate</title>
<p>The study was approved by the Ethics Committee of Southwest Hospital. The informed consent forms were obtained from the patients with HCC.</p>
</sec>
<sec>
<title>Patient consent for publication</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<glossary>
<def-list>
<title>Abbreviations</title>
<def-item><term>HCC</term><def><p>hepatocellular carcinoma</p></def></def-item>
<def-item><term>I&#x03BA;B&#x03B1;</term><def><p>NF-&#x03BA;B inhibitor &#x03B1;</p></def></def-item>
<def-item><term>IKK</term><def><p>I&#x03BA;B kinase</p></def></def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="b1-ol-0-0-12079"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Torre</surname><given-names>LA</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><volume>68</volume><fpage>394</fpage><lpage>424</lpage><year>2018</year><pub-id pub-id-type="doi">10.3322/caac.21492</pub-id><pub-id pub-id-type="pmid">30207593</pub-id></element-citation></ref>
<ref id="b2-ol-0-0-12079"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negro</surname><given-names>F</given-names></name></person-group><article-title>Natural history of NASH and HCC</article-title><source>Liver Int</source><volume>40</volume><supplement>(Suppl 1)</supplement><fpage>S72</fpage><lpage>S76</lpage><year>2020</year><pub-id pub-id-type="doi">10.1111/liv.14362</pub-id></element-citation></ref>
<ref id="b3-ol-0-0-12079"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nahon</surname><given-names>P</given-names></name><name><surname>Vibert</surname><given-names>E</given-names></name><name><surname>Nault</surname><given-names>JC</given-names></name><name><surname>Ganne-Carrie</surname><given-names>N</given-names></name><name><surname>Ziol</surname><given-names>M</given-names></name><name><surname>Seror</surname><given-names>O</given-names></name></person-group><article-title>Optimizing curative management of hepatocellular carcinoma</article-title><source>Liver Int</source><volume>40</volume><supplement>(Suppl 1)</supplement><fpage>S109</fpage><lpage>S115</lpage><year>2020</year><pub-id pub-id-type="doi">10.1111/liv.14345</pub-id></element-citation></ref>
<ref id="b4-ol-0-0-12079"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Refolo</surname><given-names>MG</given-names></name><name><surname>Messa</surname><given-names>C</given-names></name><name><surname>Guerra</surname><given-names>V</given-names></name><name><surname>Carr</surname><given-names>BI</given-names></name><name><surname>D&#x0027;Alessandro</surname><given-names>R</given-names></name></person-group><article-title>Inflammatory mechanisms of HCC development</article-title><source>Cancers (Basel)</source><volume>12</volume><fpage>641</fpage><year>2020</year><pub-id pub-id-type="doi">10.3390/cancers12030641</pub-id></element-citation></ref>
<ref id="b5-ol-0-0-12079"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohs</surname><given-names>A</given-names></name><name><surname>Kuttkat</surname><given-names>N</given-names></name><name><surname>Reissing</surname><given-names>J</given-names></name><name><surname>Zimmermann</surname><given-names>HW</given-names></name><name><surname>Sonntag</surname><given-names>R</given-names></name><name><surname>Proudfoot</surname><given-names>A</given-names></name><name><surname>Youssef</surname><given-names>SA</given-names></name><name><surname>de Bruin</surname><given-names>A</given-names></name><name><surname>Cubero</surname><given-names>FJ</given-names></name><name><surname>Trautwein</surname><given-names>C</given-names></name></person-group><article-title>Functional role of CCL5/RANTES for HCC progression during chronic liver disease</article-title><source>J Hepatol</source><volume>66</volume><fpage>743</fpage><lpage>753</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/S0168-8278(17)30756-0</pub-id><pub-id pub-id-type="pmid">28011329</pub-id></element-citation></ref>
<ref id="b6-ol-0-0-12079"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayden</surname><given-names>MS</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name></person-group><article-title>Shared principles in NF-kappaB signaling</article-title><source>Cell</source><volume>132</volume><fpage>344</fpage><lpage>362</lpage><year>2008</year><pub-id pub-id-type="doi">10.1016/j.cell.2008.01.020</pub-id><pub-id pub-id-type="pmid">18267068</pub-id></element-citation></ref>
<ref id="b7-ol-0-0-12079"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>A</given-names></name><name><surname>Levchenko</surname><given-names>A</given-names></name><name><surname>Scott</surname><given-names>ML</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group><article-title>The IkappaB-NF-kappaB signaling module: Temporal control and selective gene activation</article-title><source>Science</source><volume>298</volume><fpage>1241</fpage><lpage>1245</lpage><year>2002</year><pub-id pub-id-type="doi">10.1126/science.1071914</pub-id><pub-id pub-id-type="pmid">12424381</pub-id></element-citation></ref>
<ref id="b8-ol-0-0-12079"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>ZJ</given-names></name></person-group><article-title>Regulation of NF-&#x03BA;B by ubiquitination</article-title><source>Curr Opin Immunol</source><volume>25</volume><fpage>4</fpage><lpage>12</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.coi.2012.12.005</pub-id><pub-id pub-id-type="pmid">23312890</pub-id></element-citation></ref>
<ref id="b9-ol-0-0-12079"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Verma</surname><given-names>IM</given-names></name></person-group><article-title>NF-kappaB regulation in the immune system</article-title><source>Nat Rev Immunol</source><volume>2</volume><fpage>725</fpage><lpage>734</lpage><year>2002</year><pub-id pub-id-type="doi">10.1038/nri968</pub-id><pub-id pub-id-type="pmid">12360211</pub-id></element-citation></ref>
<ref id="b10-ol-0-0-12079"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Tu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Xiong</surname><given-names>T</given-names></name><name><surname>Fan</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Steggerda</surname><given-names>J</given-names></name><etal/></person-group><article-title>Reciprocal regulation between forkhead Box M1/NF-kB and methionine adenosyltransferase 1A drives liver cancer</article-title><source>Hepatology (Baltimore, Md.)</source><month>Feb</month><day>21</day><year>2020</year><comment>doi: 10.1002/hep.31196. Online ahead of print</comment><pub-id pub-id-type="doi">10.1002/hep.31196</pub-id></element-citation></ref>
<ref id="b11-ol-0-0-12079"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name></person-group><article-title>Missing pieces in the NF-kappaB puzzle</article-title><source>Cell</source><volume>109</volume><supplement>(Suppl)</supplement><fpage>S81</fpage><lpage>S96</lpage><year>2002</year><pub-id pub-id-type="doi">10.1016/S0092-8674(02)00703-1</pub-id><pub-id pub-id-type="pmid">11983155</pub-id></element-citation></ref>
<ref id="b12-ol-0-0-12079"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>SC</given-names></name><name><surname>Awasthee</surname><given-names>N</given-names></name><name><surname>Rai</surname><given-names>V</given-names></name><name><surname>Chava</surname><given-names>S</given-names></name><name><surname>Gunda</surname><given-names>V</given-names></name><name><surname>Challagundla</surname><given-names>KB</given-names></name></person-group><article-title>Long non-coding RNAs and nuclear factor-&#x03BA;B crosstalk in cancer and other human diseases</article-title><source>Biochim Biophys Acta Rev Cancer</source><volume>1873</volume><fpage>188316</fpage><year>2020</year><pub-id pub-id-type="doi">10.1016/j.bbcan.2019.188316</pub-id><pub-id pub-id-type="pmid">31639408</pub-id></element-citation></ref>
<ref id="b13-ol-0-0-12079"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borg</surname><given-names>JP</given-names></name><name><surname>Marchetto</surname><given-names>S</given-names></name><name><surname>Le Bivic</surname><given-names>A</given-names></name><name><surname>Ollendorff</surname><given-names>V</given-names></name><name><surname>Jaulin-Bastard</surname><given-names>F</given-names></name><name><surname>Saito</surname><given-names>H</given-names></name><name><surname>Fournier</surname><given-names>E</given-names></name><name><surname>Ad&#x00E9;la&#x00EF;de</surname><given-names>J</given-names></name><name><surname>Margolis</surname><given-names>B</given-names></name><name><surname>Birnbaum</surname><given-names>D</given-names></name></person-group><article-title>ERBIN: A basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor</article-title><source>Nat Cell Biol</source><volume>2</volume><fpage>407</fpage><lpage>414</lpage><year>2000</year><pub-id pub-id-type="doi">10.1038/35017038</pub-id><pub-id pub-id-type="pmid">10878805</pub-id></element-citation></ref>
<ref id="b14-ol-0-0-12079"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dan</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Duan</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Guo</surname><given-names>N</given-names></name></person-group><article-title>Erbin, a negative regulator in diverse signal pathways</article-title><source>Curr Protein Pept Sci</source><volume>11</volume><fpage>759</fpage><lpage>764</lpage><year>2010</year><pub-id pub-id-type="doi">10.2174/138920310794557673</pub-id><pub-id pub-id-type="pmid">21235511</pub-id></element-citation></ref>
<ref id="b15-ol-0-0-12079"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>N</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Qian</surname><given-names>L</given-names></name></person-group><article-title>Erbin loss promotes cancer cell proliferation through feedback activation of Akt-Skp2-p27 signaling</article-title><source>Biochem Biophys Res Commun</source><volume>463</volume><fpage>370</fpage><lpage>376</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.bbrc.2015.05.071</pub-id><pub-id pub-id-type="pmid">26025650</pub-id></element-citation></ref>
<ref id="b16-ol-0-0-12079"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>YZ</given-names></name><name><surname>Zang</surname><given-names>M</given-names></name><name><surname>Xiong</surname><given-names>WC</given-names></name><name><surname>Luo</surname><given-names>Z</given-names></name><name><surname>Mei</surname><given-names>L</given-names></name></person-group><article-title>Erbin suppresses the MAP kinase pathway</article-title><source>J Biol Chem</source><volume>278</volume><fpage>1108</fpage><lpage>1114</lpage><year>2003</year><pub-id pub-id-type="doi">10.1074/jbc.M205413200</pub-id><pub-id pub-id-type="pmid">12379659</pub-id></element-citation></ref>
<ref id="b17-ol-0-0-12079"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Duan</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Qian</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Hu</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>N</given-names></name></person-group><article-title>Deficiency of Erbin induces resistance of cervical cancer cells to anoikis in a STAT3-dependent manner</article-title><source>Oncogenesis</source><volume>2</volume><fpage>e52</fpage><year>2013</year><pub-id pub-id-type="doi">10.1038/oncsis.2013.18</pub-id><pub-id pub-id-type="pmid">23774064</pub-id></element-citation></ref>
<ref id="b18-ol-0-0-12079"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Yao</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>JR</given-names></name><name><surname>Guo</surname><given-names>PD</given-names></name><name><surname>Li</surname><given-names>XM</given-names></name><name><surname>Gan</surname><given-names>WJ</given-names></name><name><surname>Mei</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>TM</given-names></name><name><surname>Li</surname><given-names>JM</given-names></name></person-group><article-title>Elevated expression of Erbin destabilizes ERalpha protein and promotes tumorigenesis in hepatocellular carcinoma</article-title><source>J Hepatol</source><volume>66</volume><fpage>1193</fpage><lpage>1204</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.jhep.2017.01.030</pub-id><pub-id pub-id-type="pmid">28192186</pub-id></element-citation></ref>
<ref id="b19-ol-0-0-12079"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>FF</given-names></name><name><surname>Ollendorff</surname><given-names>V</given-names></name><name><surname>Ogura</surname><given-names>Y</given-names></name><name><surname>Marchetto</surname><given-names>S</given-names></name><name><surname>L&#x00E9;cine</surname><given-names>P</given-names></name><name><surname>Borg</surname><given-names>JP</given-names></name><name><surname>Nu&#x00F1;ez</surname><given-names>G</given-names></name></person-group><article-title>A role for Erbin in the regulation of Nod2-dependent NF-kappaB signaling</article-title><source>J Biol Chem</source><volume>280</volume><fpage>40301</fpage><lpage>40309</lpage><year>2005</year><pub-id pub-id-type="doi">10.1074/jbc.M508538200</pub-id><pub-id pub-id-type="pmid">16203728</pub-id></element-citation></ref>
<ref id="b20-ol-0-0-12079"><label>20</label><element-citation publication-type="journal"><article-title>Department of Medical Administration, National Health Commission of the People&#x0027;s Republic of China: Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)</article-title><source>Zhonghua Gan Zang Bing Za Zhi</source><volume>28</volume><fpage>112</fpage><lpage>128</lpage><year>2020</year><comment>(In Chinese)</comment><pub-id pub-id-type="pmid">32164061</pub-id></element-citation></ref>
<ref id="b21-ol-0-0-12079"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method</article-title><source>Methods</source><volume>25</volume><fpage>402</fpage><lpage>408</lpage><year>2001</year><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id><pub-id pub-id-type="pmid">11846609</pub-id></element-citation></ref>
<ref id="b22-ol-0-0-12079"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolcet</surname><given-names>X</given-names></name><name><surname>Llobet</surname><given-names>D</given-names></name><name><surname>Pallares</surname><given-names>J</given-names></name><name><surname>Matias-Guiu</surname><given-names>X</given-names></name></person-group><article-title>NF-&#x03BA;B in development and progression of human cancer</article-title><source>Virchows Arch</source><volume>446</volume><fpage>475</fpage><lpage>482</lpage><year>2005</year><pub-id pub-id-type="doi">10.1007/s00428-005-1264-9</pub-id><pub-id pub-id-type="pmid">15856292</pub-id></element-citation></ref>
<ref id="b23-ol-0-0-12079"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Gong</surname><given-names>C</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Lv</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Yao</surname><given-names>H</given-names></name><name><surname>Su</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><etal/></person-group><article-title>A cytoplasmic NF-&#x03BA;B interacting long noncoding RNA blocks I&#x03BA;B phosphorylation and suppresses breast cancer metastasis</article-title><source>Cancer Cell</source><volume>27</volume><fpage>370</fpage><lpage>381</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.ccell.2015.02.004</pub-id><pub-id pub-id-type="pmid">25759022</pub-id></element-citation></ref>
<ref id="b24-ol-0-0-12079"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Zuo</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Song</surname><given-names>X</given-names></name></person-group><article-title>Lapatinib inhibits the activation of NF-&#x03BA;B through reducing phosphorylation of I&#x03BA;B-&#x03B1; in breast cancer cells</article-title><source>Oncol Rep</source><volume>29</volume><fpage>812</fpage><lpage>818</lpage><year>2013</year><pub-id pub-id-type="doi">10.3892/or.2012.2159</pub-id><pub-id pub-id-type="pmid">23229346</pub-id></element-citation></ref>
<ref id="b25-ol-0-0-12079"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ataie-Kachoie</surname><given-names>P</given-names></name><name><surname>Badar</surname><given-names>S</given-names></name><name><surname>Morris</surname><given-names>DL</given-names></name><name><surname>Pourgholami</surname><given-names>MH</given-names></name></person-group><article-title>Minocycline targets the NF-&#x03BA;B Nexus through suppression of TGF-&#x03B2;1-TAK1-I&#x03BA;B signaling in ovarian cancer</article-title><source>Mol Cancer Res</source><volume>11</volume><fpage>1279</fpage><lpage>1291</lpage><year>2013</year><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-13-0239</pub-id><pub-id pub-id-type="pmid">23858099</pub-id></element-citation></ref>
<ref id="b26-ol-0-0-12079"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhoads</surname><given-names>MG</given-names></name><name><surname>Kandarian</surname><given-names>SC</given-names></name><name><surname>Pacelli</surname><given-names>F</given-names></name><name><surname>Doglietto</surname><given-names>GB</given-names></name><name><surname>Bossola</surname><given-names>M</given-names></name></person-group><article-title>Expression of NF-kappaB and IkappaB proteins in skeletal muscle of gastric cancer patients</article-title><source>Eur J Cancer</source><volume>46</volume><fpage>191</fpage><lpage>197</lpage><year>2010</year><pub-id pub-id-type="doi">10.1016/j.ejca.2009.10.008</pub-id><pub-id pub-id-type="pmid">19857958</pub-id></element-citation></ref>
<ref id="b27-ol-0-0-12079"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>YX</given-names></name><name><surname>Ju</surname><given-names>HQ</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>LZ</given-names></name><name><surname>Wu</surname><given-names>QN</given-names></name><name><surname>Sheng</surname><given-names>H</given-names></name><name><surname>Mo</surname><given-names>HY</given-names></name><name><surname>Pan</surname><given-names>ZZ</given-names></name><name><surname>Xie</surname><given-names>D</given-names></name><name><surname>Kang</surname><given-names>TB</given-names></name><etal/></person-group><article-title>Inhibition of the NF-&#x03BA;B pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis</article-title><source>Cancer Lett</source><volume>380</volume><fpage>87</fpage><lpage>97</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/j.canlet.2016.06.014</pub-id><pub-id pub-id-type="pmid">27322737</pub-id></element-citation></ref>
<ref id="b28-ol-0-0-12079"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feld</surname><given-names>JJ</given-names></name><name><surname>Krassenburg</surname><given-names>LAP</given-names></name></person-group><article-title>What comes first: Treatment of viral hepatitis or liver cancer?</article-title><source>Dig Dis Sci</source><volume>64</volume><fpage>1041</fpage><lpage>1049</lpage><year>2019</year><pub-id pub-id-type="doi">10.1007/s10620-019-05518-5</pub-id><pub-id pub-id-type="pmid">30874985</pub-id></element-citation></ref>
<ref id="b29-ol-0-0-12079"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><article-title>At the crossroads of inflammation and cancer</article-title><source>Cell</source><volume>118</volume><fpage>671</fpage><lpage>674</lpage><year>2004</year><pub-id pub-id-type="doi">10.1016/j.cell.2004.09.005</pub-id><pub-id pub-id-type="pmid">15369667</pub-id></element-citation></ref>
<ref id="b30-ol-0-0-12079"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pikarsky</surname><given-names>E</given-names></name><name><surname>Porat</surname><given-names>RM</given-names></name><name><surname>Stein</surname><given-names>I</given-names></name><name><surname>Abramovitch</surname><given-names>R</given-names></name><name><surname>Amit</surname><given-names>S</given-names></name><name><surname>Kasem</surname><given-names>S</given-names></name><name><surname>Gutkovich-Pyest</surname><given-names>E</given-names></name><name><surname>Urieli-Shoval</surname><given-names>S</given-names></name><name><surname>Galun</surname><given-names>E</given-names></name><name><surname>Ben-Neriah</surname><given-names>Y</given-names></name></person-group><article-title>NF-kappaB functions as a tumour promoter in inflammation-associated cancer</article-title><source>Nature</source><volume>431</volume><fpage>461</fpage><lpage>466</lpage><year>2004</year><pub-id pub-id-type="doi">10.1038/nature02924</pub-id><pub-id pub-id-type="pmid">15329734</pub-id></element-citation></ref>
<ref id="b31-ol-0-0-12079"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elsharkawy</surname><given-names>AM</given-names></name><name><surname>Mann</surname><given-names>DA</given-names></name></person-group><article-title>Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis</article-title><source>Hepatology</source><volume>46</volume><fpage>590</fpage><lpage>597</lpage><year>2007</year><pub-id pub-id-type="doi">10.1002/hep.21802</pub-id><pub-id pub-id-type="pmid">17661407</pub-id></element-citation></ref>
<ref id="b32-ol-0-0-12079"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>PD</given-names></name><name><surname>Wen</surname><given-names>YA</given-names></name><name><surname>Xiong</surname><given-names>X</given-names></name><name><surname>Zaytseva</surname><given-names>YY</given-names></name><name><surname>Li</surname><given-names>AT</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Stevens</surname><given-names>AT</given-names></name><name><surname>Farmer</surname><given-names>TN</given-names></name><name><surname>Gan</surname><given-names>T</given-names></name><name><surname>Weiss</surname><given-names>HL</given-names></name><etal/></person-group><article-title>Erbin suppresses KSR1-mediated RAS/RAF signaling and tumorigenesis in colorectal cancer</article-title><source>Cancer Res</source><volume>78</volume><fpage>4839</fpage><lpage>4852</lpage><year>2018</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-3629</pub-id><pub-id pub-id-type="pmid">29980571</pub-id></element-citation></ref>
<ref id="b33-ol-0-0-12079"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Duan</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Duan</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>N</given-names></name></person-group><article-title>Downregulation of Erbin in Her2-overexpressing breast cancer cells promotes cell migration and induces trastuzumab resistance</article-title><source>Mol Immunol</source><volume>56</volume><fpage>104</fpage><lpage>112</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.molimm.2013.04.007</pub-id><pub-id pub-id-type="pmid">23711387</pub-id></element-citation></ref>
<ref id="b34-ol-0-0-12079"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>CM</given-names></name><name><surname>Wei</surname><given-names>D</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Marchetto</surname><given-names>S</given-names></name><name><surname>Mei</surname><given-names>L</given-names></name><name><surname>Borg</surname><given-names>JP</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name></person-group><article-title>Erbin is a novel substrate of the Sag-&#x03B2;TrCP E3 ligase that regulates KrasG12D-induced skin tumorigenesis</article-title><source>J Cell Biol</source><volume>209</volume><fpage>721</fpage><lpage>737</lpage><year>2015</year><pub-id pub-id-type="doi">10.1083/jcb.201411104</pub-id><pub-id pub-id-type="pmid">26056141</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-ol-0-0-12079" position="float">
<label>Figure 1.</label>
<caption><p>I&#x03BA;B&#x03B1; expression is downregulated in HCC and associated with poor prognosis of patients with HCC. (A) Representative images of HCC and adjacent liver tissues from 107 cases stained with anti-I&#x03BA;B&#x03B1; antibody. (B) Association between OS time of 107 patients with HCC and I&#x03BA;B&#x03B1; expression. Cells were transfected with (C) siI&#x03BA;B&#x03B1; or (D) HA-I&#x03BA;B&#x03B1; and proliferation was assessed after 24 h of transfection using Cell Counting Kit-8 assay. Cells were transfected with (E) siI&#x03BA;B&#x03B1; or (F) HA-I&#x03BA;B&#x03B1; for 48 h and proliferation was assessed with a clonogenic survival assay. Cells were transfected with (G) siI&#x03BA;B&#x03B1; or (H) HA-I&#x03BA;B&#x03B1; for 48 h and then analyzed with a Transwell migration assay. Scale bar, 100 &#x00B5;m. Error bars represent SEM from three independent experiments. &#x002A;P&#x003C;0.05, &#x002A;&#x002A;P&#x003C;0.01 and &#x002A;&#x002A;&#x002A;P&#x003C;0.001 vs. corresponding control group. siRNA, small interfering RNA; I&#x03BA;B&#x03B1;, NF-&#x03BA;B inhibitor &#x03B1;; Cont, control; HCC, hepatocellular carcinoma; OS, overall survival; HA-I&#x03BA;B&#x03B1;, overexpression plasmid.</p></caption>
<graphic xlink:href="ol-20-05-12079-g00.tif"/>
</fig>
<fig id="f2-ol-0-0-12079" position="float">
<label>Figure 2.</label>
<caption><p>I&#x03BA;B&#x03B1; negatively regulates Erbin expression via NF-&#x03BA;B. (A) Representative images of HCC and adjacent liver tissues from 107 cases stained with anti-Erbin antibody. (B) Association between OS time of 107 patients with HCC and Erbin expression. Cells were transfected with (C) siI&#x03BA;B&#x03B1; or (D) HA-I&#x03BA;B&#x03B1; for 48 h and Erbin expression was determined using western blot analysis. Cells were transfected with (E) siI&#x03BA;B&#x03B1; or (F) HA-I&#x03BA;B&#x03B1; for 48 h and NF-&#x03BA;B p65 expression was determined using western blot analysis. (G) Cells were transfected with siI&#x03BA;B&#x03B1; for 48 h and mRNA expression levels of c-Rel and Ezh2 were assessed using RT-qPCR. Cells were transfected with (H) Flag-NF-&#x03BA;B p65 or (I) siNF-&#x03BA;B p65 for 48 h and then the mRNA expression of Erbin was measured using RT-qPCR. Cells were transfected with (J) Flag-NF-&#x03BA;B p65 or (K) siNF-&#x03BA;B p65 for 48 h, then Erbin expression was determined using western blot analysis. Scale bar, 100 &#x00B5;m. The error bars represent SEM from three independent experiments. &#x002A;P&#x003C;0.05, &#x002A;&#x002A;P&#x003C;0.01 and &#x002A;&#x002A;&#x002A;P&#x003C;0.001 vs. corresponding control group. siRNA, small interfering RNA; I&#x03BA;B&#x03B1;, NF-&#x03BA;B inhibitor &#x03B1;; Cont, control; HCC, hepatocellular carcinoma; OS, overall survival; Erbin, Erbb2 interacting protein; RT-qPCR, reverse transcription-quantitative PCR; Rel, Rel proto-oncogene, NF-kB subunit; Ezh2, enhancer of zeste 2 polycomb repressive complex 2 subunit.</p></caption>
<graphic xlink:href="ol-20-05-12079-g01.tif"/>
</fig>
<fig id="f3-ol-0-0-12079" position="float">
<label>Figure 3.</label>
<caption><p>I&#x03BA;B&#x03B1; is negatively associated with Erbin in patients with HCC. (A) Representative images of HCC and adjacent liver tissues from 107 cases stained with anti-I&#x03BA;B&#x03B1; and anti-Erbin antibodies. (B) There was a negative association between I&#x03BA;B&#x03B1; and Erbin expression levels. Scale bar, 100 &#x00B5;m. Erbin, Erbb2 interacting protein; I&#x03BA;B&#x03B1;, NF-&#x03BA;B inhibitor &#x03B1;; HCC, hepatocellular carcinoma.</p></caption>
<graphic xlink:href="ol-20-05-12079-g02.tif"/>
</fig>
<fig id="f4-ol-0-0-12079" position="float">
<label>Figure 4.</label>
<caption><p>Erbin is responsible for NF-&#x03BA;B-mediated HCC cell proliferation and migration. Cells were transfected with (A) HA-Erbin or (B) siErbin for 48 h and Erbin expression was determined by western blotting. Cells were transfected with (C) HA-Erbin or (D) siErbin and cell proliferation was assessed after 24 h of transfection using CCK-8 assay. After transfection with (E) HA-Erbin or (F) siErbin for 48 h, cells were seeded into Transwell plate for 24 h and stained with 0.1&#x0025; crystal violet staining solution. Cells were transfected with Flag-NF-&#x03BA;B p65, with or without Erbin siRNA, and analyzed using (G) western blotting, (H) CCK-8 assay or (I) Transwell migration assay. Scale bar, 100 &#x00B5;m. The error bars represent SEM from three independent experiments. &#x002A;P&#x003C;0.05, &#x002A;&#x002A;P&#x003C;0.01 and &#x002A;&#x002A;&#x002A;P&#x003C;0.001 vs. corresponding control group. siRNA, small interfering RNA; I&#x03BA;B&#x03B1;, NF-&#x03BA;B inhibitor &#x03B1;; Cont, control; Erbin, Erbb2 interacting protein; CCK-8, Cell Counting Kit-8.</p></caption>
<graphic xlink:href="ol-20-05-12079-g03.tif"/>
</fig>
<table-wrap id="tI-ol-0-0-12079" position="float">
<label>Table I.</label>
<caption><p>Association between I&#x03BA;B&#x03B1; expression and clinicopathological variables of 107 patients with HCC.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th/>
<th align="center" valign="bottom" colspan="2">I&#x03BA;B&#x03B1; expression</th>
<th/>
<th/>
</tr>
<tr>
<th/>
<th align="center" valign="bottom" colspan="2"><hr/></th>
<th/>
<th/>
</tr>
<tr>
<th align="left" valign="bottom">Parameter</th>
<th align="center" valign="bottom">High (n=24)</th>
<th align="center" valign="bottom">Low (n=83)</th>
<th align="center" valign="bottom">&#x03C7;<sup>2</sup></th>
<th align="center" valign="bottom">P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Sex</td>
<td/>
<td/>
<td align="center" valign="top">0.873</td>
<td align="center" valign="top">0.35</td>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;Male</td>
<td align="center" valign="top">19</td>
<td align="center" valign="top">74</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;Female</td>
<td align="center" valign="top">5</td>
<td align="center" valign="top">9</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">Age, years</td>
<td/>
<td/>
<td align="center" valign="top">0.97</td>
<td align="center" valign="top">0.325</td>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;&#x2264;50</td>
<td align="center" valign="top">17</td>
<td align="center" valign="top">49</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;&#x003E;50</td>
<td align="center" valign="top">7</td>
<td align="center" valign="top">33</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">TNM stage</td>
<td/>
<td/>
<td align="center" valign="top">0.410</td>
<td align="center" valign="top">0.522</td>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;I</td>
<td align="center" valign="top">11</td>
<td align="center" valign="top">32</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;II&#x2013;IV</td>
<td align="center" valign="top">13</td>
<td align="center" valign="top">51</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">Tumor thrombi</td>
<td/>
<td/>
<td align="center" valign="top">1.706</td>
<td align="center" valign="top">0.192</td>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;Yes</td>
<td align="center" valign="top">4</td>
<td align="center" valign="top">25</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;No</td>
<td align="center" valign="top">20</td>
<td align="center" valign="top">58</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">Histological grade</td>
<td/>
<td/>
<td align="center" valign="top">0.001</td>
<td align="center" valign="top">0.98</td>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;I</td>
<td align="center" valign="top">3</td>
<td align="center" valign="top">8</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;II&#x2013;III</td>
<td align="center" valign="top">21</td>
<td align="center" valign="top">75</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">Intrahepatic metastasis</td>
<td/>
<td/>
<td align="center" valign="top">0.363</td>
<td align="center" valign="top">0.547</td>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;Yes</td>
<td align="center" valign="top">6</td>
<td align="center" valign="top">14</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;No</td>
<td align="center" valign="top">18</td>
<td align="center" valign="top">69</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">Tumor recurrence</td>
<td/>
<td/>
<td align="center" valign="top">7.035</td>
<td align="center" valign="top">0.008<sup><xref rid="tfn2-ol-0-0-12079" ref-type="table-fn">a</xref></sup></td>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;Yes</td>
<td align="center" valign="top">10</td>
<td align="center" valign="top">59</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;No</td>
<td align="center" valign="top">14</td>
<td align="center" valign="top">24</td>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn1-ol-0-0-12079"><p>Statistical analyses were performed using Pearson &#x03C7;<sup>2</sup> test.</p></fn>
<fn id="tfn2-ol-0-0-12079"><label>a</label><p>P&#x003C;0.05. I&#x03BA;B&#x03B1;, NF-&#x03BA;B inhibitor &#x03B1;.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tII-ol-0-0-12079" position="float">
<label>Table II.</label>
<caption><p>Association between Erbin expression and clinicopathological variables of 107 patients with HCC.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th/>
<th align="center" valign="bottom" colspan="2">Erbin expression</th>
<th/>
<th/>
</tr>
<tr>
<th/>
<th align="center" valign="bottom" colspan="2"><hr/></th>
<th/>
<th/>
</tr>
<tr>
<th align="left" valign="bottom">Parameter</th>
<th align="center" valign="bottom">High (n=63)</th>
<th align="center" valign="bottom">Low (n=44)</th>
<th align="center" valign="bottom">&#x03C7;<sup>2</sup></th>
<th align="center" valign="bottom">P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Sex</td>
<td/>
<td/>
<td align="center" valign="top">0.195</td>
<td align="center" valign="top">0.659</td>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;Male</td>
<td align="center" valign="top">54</td>
<td align="center" valign="top">39</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;Female</td>
<td align="center" valign="top">9</td>
<td align="center" valign="top">5</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">Age, years</td>
<td/>
<td/>
<td align="center" valign="top">0.009</td>
<td align="center" valign="top">0.926</td>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;&#x2264;50</td>
<td align="center" valign="top">39</td>
<td align="center" valign="top">27</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;&#x003E;50</td>
<td align="center" valign="top">24</td>
<td align="center" valign="top">16</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">TNM stage</td>
<td/>
<td/>
<td align="center" valign="top">4.541</td>
<td align="center" valign="top">0.033<sup><xref rid="tfn4-ol-0-0-12079" ref-type="table-fn">a</xref></sup></td>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;I</td>
<td align="center" valign="top">20</td>
<td align="center" valign="top">23</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;II&#x2013;IV</td>
<td align="center" valign="top">43</td>
<td align="center" valign="top">21</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">Tumor thrombi</td>
<td/>
<td/>
<td align="center" valign="top">4.739</td>
<td align="center" valign="top">0.029<sup><xref rid="tfn4-ol-0-0-12079" ref-type="table-fn">a</xref></sup></td>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;Yes</td>
<td align="center" valign="top">22</td>
<td align="center" valign="top">7</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;No</td>
<td align="center" valign="top">41</td>
<td align="center" valign="top">37</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">Histological grade</td>
<td/>
<td/>
<td align="center" valign="top">0.000</td>
<td align="center" valign="top">0.988</td>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;I</td>
<td align="center" valign="top">7</td>
<td align="center" valign="top">4</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;II&#x2013;III</td>
<td align="center" valign="top">56</td>
<td align="center" valign="top">40</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">Intrahepatic metastasis</td>
<td/>
<td/>
<td align="center" valign="top">2.640</td>
<td align="center" valign="top">0.014</td>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;Yes</td>
<td align="center" valign="top">15</td>
<td align="center" valign="top">5</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;No</td>
<td align="center" valign="top">48</td>
<td align="center" valign="top">39</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">Tumor recurrence</td>
<td/>
<td/>
<td align="center" valign="top">9.165</td>
<td align="center" valign="top">0.002<sup><xref rid="tfn4-ol-0-0-12079" ref-type="table-fn">a</xref></sup></td>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;Yes</td>
<td align="center" valign="top">48</td>
<td align="center" valign="top">21</td>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;No</td>
<td align="center" valign="top">15</td>
<td align="center" valign="top">23</td>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn3-ol-0-0-12079"><p>Statistical analyses were performed using Pearson &#x03C7;<sup>2</sup> test.</p></fn>
<fn id="tfn4-ol-0-0-12079"><label>a</label><p>P&#x003C;0.05. Erbin, Erbb2 interacting protein.</p></fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
